Last €8.90 EUR
Change Today +0.01 / 0.11%
Volume 5.8K
ROVI On Other Exchanges
Symbol
Exchange
Berlin
Continuous
As of 11:38 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

laboratorios farmaceuticos r (ROVI) Snapshot

Open
€8.99
Previous Close
€8.89
Day High
€8.99
Day Low
€8.81
52 Week High
01/21/14 - €10.23
52 Week Low
09/27/13 - €7.65
Market Cap
445.0M
Average Volume 10 Days
12.6K
EPS TTM
€0.48
Shares Outstanding
50.0M
EX-Date
07/3/14
P/E TM
18.6x
Dividend
€0.16
Dividend Yield
1.82%
Current Stock Chart for LABORATORIOS FARMACEUTICOS R (ROVI)

Related News

No related news articles were found.

laboratorios farmaceuticos r (ROVI) Related Businessweek News

No Related Businessweek News Found

laboratorios farmaceuticos r (ROVI) Details

Laboratorios Farmacéuticos ROVI, S.A. engages in the research, development, in licensing, manufacturing, and marketing of small molecule and specialty biologic drugs in Spain and internationally. Its principal product includes Bemiparin, a low molecular weight heparin. The company’s prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat post-menopausal osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Pneumovax-23, a vaccine for immunization against pneumococcal illness; Glufan for relieving symptoms of degenerative osteoarthritis; and Corlentor for treating chronic stable angina pectoris. Its prescription products also include Exxiv for relieving the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylarthritis, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; and Thymanax for treating depressive episodes in adults. In addition, the company offers diagnostic products, such as SonoVue contrast medium for use with ultrasound imaging; and Iopamiro and Iomeron contrast media for diagnosis by computed tomography; and Multihance And Prohance for use in diagnostic magnetic resonance imaging, as well as OTC products comprising Perspirex to control sweating from the armpits; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; and ColdPack cold and hot bag for reliving pain. Further, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmacéuticos ROVI, S.A. is a subsidiary of Inversiones Clidia, S.L.

1,053 Employees
Last Reported Date: 07/30/14
Founded in 1946

laboratorios farmaceuticos r (ROVI) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €410.0K
Chairman of The Board, Chief Executive Office...
Total Annual Compensation: €244.0K
Chief Financial Officer, Director and Member ...
Total Annual Compensation: €305.0K
Director of Corporate Development and Directo...
Total Annual Compensation: €303.0K
Compensation as of Fiscal Year 2013.

laboratorios farmaceuticos r (ROVI) Key Developments

Laboratorios Farmaceuticos ROVI, S.A. Reports Consolidated Earnings Results for the First Half Ended June 30, 2014; provides earnings guidance for the year 2014

Laboratorios Farmaceuticos ROVI, S.A. reported consolidated earnings results for the first half ended June 30, 2014. For the first half, the company reported revenue of EUR 117.9 million compared to EUR 110.3 million a year ago. EBITDA was EUR 20.9 million compared to EUR 18.4 million a year ago. EBIT was EUR 16.6 million compared to EUR 15.2 million a year ago. Net profit was EUR 15 million compared to EUR 13.8 million a year ago. Operating revenue increased by 6% driven by the strength of the specialty pharmaceutical business, where sales rose 9% to EUR 86.1 million. EBITDA increased by 14% reflecting a 1.2 percentage points rise in the EBITDA margin to 18.0% in the first half of 2014 up from 16.8% in the first half of 2013. EBIT increased by 10% reflecting a 0.5 percentage point rise in the EBIT margin to 14.3% up from 13.8% in the first half of 2013. Financial income increased by 91% in the first half of 2014, compared to the same period of the previous year, mainly as a result of higher returns on financial investments. The company invested EUR 6.6 million in the first half of 2014, compared to EUR 6.8 million in the first half of 2013. Net cash generated from operating activities was EUR 8.762 million compared to EUR 10.348 million a year ago. Purchases of property, plant and equipment was EUR 5.579 million compared to EUR 3.902 million a year ago. Purchases of intangible assets was EUR 0.980 million compared to EUR 2.891 million a year ago. The company expects capital expenditure for the year 2014 to be below the 2013 figure (EUR 24.7 million), but above the 2012 level (EUR 13.7 million) due to the investments related to the Risperidone-ISM® project. The company expects a mid-to-high single digit growth rate for the operating revenue despite a 2% contraction in the Spanish pharmaceutical market as forecast by Farmaindustria1, the Spanish Pharmaceutical Association, and the continued decreases in the pharmacy retail market at least until 2017 forecast by IMS Health.

Laboratorios Farmaceuticos ROVI, S.A. to Report First Half, 2014 Results on Jul 30, 2014

Laboratorios Farmaceuticos ROVI, S.A. announced that they will report first half, 2014 results on Jul 30, 2014

Laboratorios Farmaceuticos ROVI, S.A., H1 2014 Earnings Call, Jul 30, 2014

Laboratorios Farmaceuticos ROVI, S.A., H1 2014 Earnings Call, Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROVI:SM €8.90 EUR +0.01

ROVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ROVI.
View Industry Companies
 

Industry Analysis

ROVI

Industry Average

Valuation ROVI Industry Range
Price/Earnings 17.2x
Price/Sales 1.8x
Price/Book 2.7x
Price/Cash Flow 13.0x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORIOS FARMACEUTICOS R, please visit www.rovi.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.